George Yancopoulos, Regeneron president and CSO (Brendan McDermid/Reuters/Alamy)
In surprise flop, Regeneron, Sanofi report Dupixent PhIII failure, triggering premature trial stop
Dupixent, the seemingly infallible anti-inflammatory drug jointly developed by Regeneron and Sanofi, has flopped in a Phase III study.
Given to patients with chronic spontaneous …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
